# US 2010/0168113 A1 · Pharmaceutical Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168113 A1
- Document ID: US20100168113A1
- Status: Published application
- Kind: A1
- Application number: 12/226,260
- Filed: 2007-04-10
- Published: 2010-07-01
- Earliest claimed: 2007-04-10
- Assignees: Bial - Portela & Ca, S.A.
- Inventors: David Alexander Learmonth; Laszlo Erno Kiss; Pedro Nuno Leal Palma; Humberto Dos Santos Ferreira; Patricio Manuel Vieira Soares da Silva
- Web page: https://patentgrep.com/patent/US20100168113A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/26: Radicals substituted by halogen atoms or nitro radicals
- C07D 213/57: Nitriles
- C07D 213/82: in position 3
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.

## Claims

### Claim 1

A compound of formula I:
wherein R1 and R2 are independently from each other hydrogen or a group which is hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl; X represents a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R3 represents a pyridine group according to the formula A, B or C, which is connected as indicated by the unmarked bond:
where R4, R5, R6 and R7 independently from each other represent hydrogen, C1-C6-alkyl, C1-C6-thioalkyl, C1-C6-alkoxy, C6-C12-aryloxy or a C6-C12-thioaryl group, C1-C6-alkanoyl or C7-C13-aroyl group, amino, C1-C6— alkylamino, C1-C6-dialkylamino, C3-C12-cycloalkylamino, C3-C12-heterocycloalkylamino, C1-C6-alkylsulphonyl, C6-C12-arylsulphonyl, halogen, C1-C6-haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group; or two or more of residues R4, R5, R6 and R7 taken together represent aliphatic or heteroaliphatic rings or aromatic or hetero aromatic rings and wherein P represents a central unit, which is preferably a planar unit and which is even more preferably selected from the regioisomers of 1,3,4-oxadiazol-2,5-diyl, 1,2,4-oxadiazol-3,5-diyl, 4-methyl-4H-1,2,4-triazol-3,5-diyl, 1,3,5-triazin-2,4-diyl, 1,2,4-triazin-3,5-diyl, 2H-tetrazol-2,5-diyl, 1,2,3-thiadiazol-4,5-diyl, 1-alkyl-3-(alkoxycarbonyl)-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl and wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, 1-alkyl-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl, thiazol-2,4-diyl, 1-H-pyrazol-1,5-diyl, pyrimidin-2,4-diyl, oxazol-2,4-diyl, carbonyl, 1H-imidazol-1,5-diyl, isoxazol-3,5-diyl, furan-2,4-diyl, 3-alkoxycarbonylfuran-2,4-diyl, wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, benzene-1,3-diyl and (Z)-1-cyanoethen-1,2-diyl; or a pharmaceutically acceptable salt or ester of a compound of formula I.

### Claim 2 (depends on 1)

A compound, salt or ester according to claim 1, wherein the compound of formula I is selected from 3-nitro-5-(3-(4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)benzene-1,2-diol, 5-(3-(2-chloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-methyl-6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(3-(6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)benzene-1,2-diol, 5-(3-(6-methyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2,6-dimethyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(3,5-dichloropyridin-4-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(6-methyl-2-phenyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-bromo-4,5,6-trimethylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-chloro-4,5,6-trimethylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(3-(2-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)benzene-1,2-diol, 5-(3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(3-(5-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)benzene-1,2-diol, 5-(3-(2-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(6-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-chloro-6-methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-bromo-6-methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 5-(3-(2-bromo-5-chloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(5-(4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)benzene-1,2-diol, 5-(5-(2-chloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-methyl-6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(5-(6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)benzene-1,2-diol, 5-(5-(6-methyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2,6-dimethyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(3,5-dichloropyridin-4-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(6-methyl-2-phenyl-4-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-bromo-4,5,6-trimethylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-chloro-4,5,6-trimethylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(5-(2-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)benzene-1,2-diol, 5-(5-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 3-nitro-5-(5-(5-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)benzene-1,2-diol, 5-(5-(2-fluoropyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-fluoropyridin-4-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(6-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl)-3-nitro benzene-1,2-diol, 5-(5-(2-chloro-6-methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-bromo-6-methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol, 5-(5-(2-bromo-5-chloro-4,6-dimethylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-nitrobenzene-1,2-diol.

### Claim 3 (depends on 1)

A compound, salt or ester according to claim 1, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.

### Claim 4 (depends on 1)

A compound, salt or ester according to claim 1 for use as an active ingredient in a pharmaceutical composition.

### Claim 5 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising a compound, salt or ester according to any one of claims 1 to 4.

### Claim 6 (depends on 5)

A pharmaceutical composition as claimed in claim 5, further comprising L-DOPA.

### Claim 7 (depends on 5, 6)

A pharmaceutical composition as claimed in claim 5 or 6, further comprising an aromatic L-amino acid decarboxylase inhibitor.

### Claim 8 (depends on 7)

A pharmaceutical composition according to claim 7, wherein the DOPA decarboxylase inhibitor is a DOPA decarboxylase inhibitor selected from benserazide or carbidopa.

### Claim 9 (depends on 1, 2, 3, 4)

Use of a compound, salt, ester or composition according to any one of claims 1 to 4 for the preparation of a pharmaceutical composition for the treatment of a central and peripheral nervous system disorder.

### Claim 10 (depends on 1, 2, 3, 4)

Use of a compound, salt, ester or composition according to any one of claims 1 to 4 for the treatment of a central and peripheral nervous system disorder.

### Claim 11 (depends on 9, 10)

Use as claimed in claim 9 or 10 wherein the central and peripheral nervous system disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.

### Claim 12 (depends on 11)

Use as claimed in claim 11 wherein the movement disorder is restless leg syndrome, Parkinson's disease or a pathological state involving Parkinsonism.

### Claim 13 (depends on 5, 6, 7, 8)

Method of treatment of a central and peripheral nervous system disorder, comprising the step of administering an effective dose of a pharmaceutical composition as claimed in any of claims 5 to 8 to a subject in need thereof.

### Claim 14 (depends on 13)

Method as claimed in claim 13, wherein the central and peripheral nervous system disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.

### Claim 15 (depends on 14)

Method as claimed in claim 14, wherein the movement disorder is Parkinson's disease or a pathological state involving Parkinsonism.

### Claim 16 (depends on 1, 2, 3, 4)

Method of reducing COMT activity in a subject, comprising the step of administering an effective amount of a compound, salt, ester or composition according to any one of claims 1 to 4 to a subject in need thereof.

### Claim 17 (depends on 1, 2, 3, 4)

Method of increasing levels of L-DOPA in the brain or plasma of a subject, comprising the step of administering an effective amount of a compound, salt, ester or composition according to any one of claims 1 to 4 to a subject in need thereof.

### Claim 18 (depends on 1, 2, 3, 4)

Method of increasing bio availability of L-DOPA in the brain or plasma of a subject, comprising the step of administering an effective amount of a compound, salt, ester or composition according to any one of claims 1 to 4 to a subject in need thereof.

### Claim 19 (depends on 1, 2, 3, 4)

Method of decreasing levels of 3-O-methyl-L-DOPA (3-OMD) in the brain or plasma of a subject, comprising the step of administering an effective amount of a compound, salt, ester or composition according to any one of claims 1 to 4 to a subject in need thereof.

### Claim 20 (depends on 13, 14, 15, 16, 17, 18, 19)

Method as claimed in any of claims 13 to 19 wherein the pharmaceutical composition or the compound is administered from twice per day to once every other day.

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19)

Method as claimed in any of claims 13 to 19 wherein the pharmaceutical composition is administered once per day.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21)

Method as claimed in any of claims 13 to 21 wherein the subject is also receiving therapy with L-DOPA.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

Method as claimed in any of claims 13 to 22 wherein the subject is also receiving therapy with an aromatic L-amino acid decarboxylase inhibitor.

### Claim 24 (depends on 23)

Method as claimed in claim 23 wherein the aromatic L-amino acid decarboxylase inhibitor is a DOPA decarboxylase inhibitor selected from benserazide and carbidopa.

### Claim 25 (depends on 1)

Process for the preparation of compounds according to the general formula I in claim 1 wherein P represents a 1,2,4-oxadiazolyl group, said process comprising steps wherein a compound of formula VA, VB or VC,
wherein R4, R5, R6 and R7 are defined as in the general formula I in claim 1, is subjected to cyclisation with a compound of formula III under conditions suitable to produce oxadiazole derivatives of formula VIA, VIB or VIC,
optionally followed by removal of the protecting groups R8 and/or R9.

### Claim 26 (depends on 25)

Process according to claim 25, wherein the compound of formula III is activated by reaction with thionyl chloride or 1,1-carbonyldiimidazole.

### Claim 27 (depends on 25, 26)

Process according to claim 25 or 26, wherein the cyclisation step consisting of condensation and dehydration is conducted sequentially in a one-pot reaction.

### Claim 28 (depends on 25, 26, 27)

Process according to any one of claims 25 to 27, wherein the cyclisation step is carried out in the presence of a suitable organic base.

### Claim 29 (depends on 28)

Process according to claim 28, wherein the cyclisation step is carried out in the presence of pyridine.

### Claim 30 (depends on 25, 26, 27, 28, 29)

Process according to any one of claims 25 to 29 wherein the groups R8 and R9 are independently from each other or jointly removed and replaced with hydrogen or a group which is hydrolysable under physiological conditions.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

Process according to any one of claims 25 to 30 wherein R8 and R9 of the compound of formula III independently from each other represent methyl or hydrogen.

### Claim 32 (depends on 31)

Process according to claim 31, wherein the methyl group is removed by reaction with aluminium chloride and pyridine in N-methylpyrrolidinone.

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

Process according to any one of claims 25 to 32, wherein the condensation and dehydration is performed in a dipolar aprotic solvent.

### Claim 34 (depends on 33)

Process according to claim 33, wherein the condensation and dehydration is performed in dimethylacetamide, N-methylpyrrolidinone or dimethylsulfoxide.

### Claim 35 (depends on 1, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

Process according to any one of claims 25 to 34, wherein the compound of formula VA, VB or VC is obtained by the reaction of compound VIIIA, VIIIB or VIIIC, respectively,
wherein R4, R5, R4 and R7 are defined as in the general formula I in claim 1, with hydroxylamine in the presence of a chelating agent under conditions suitable to produce amidoxime derivatives.

### Claim 36 (depends on 35)

Process according to claim 35, wherein the chelating agent is selected from the group consisting of 8-hydroxyquinoline, ortho-phenanthroline and hydrates or derivatives thereof.

### Claim 37 (depends on 1)

Use of a compound of formula I as defined in claim 1, or a pharmacologically acceptable salt or ester thereof, for the preparation of a medicament for administration according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day, for the prevention or treatment of central and peripheral nervous system associated disorders.

### Claim 38 (depends on 37)

Use according to claim 37, wherein the dosing regimen is once daily.

### Claim 39 (depends on 37)

Use according to claim 37, wherein the dosing regimen is once every other day.

### Claim 40 (depends on 37, 38, 39)

Use according to any one of claims 37 to 39, wherein the central and peripheral nervous system associated disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.

### Claim 41 (depends on 40)

Method as claimed in claim 40, wherein the movement disorder is restless leg syndrome, Parkinson's disease or a pathological state involving Parkinsonism.

### Claim 42 (depends on 37, 38, 39, 40, 41)

Use according to any one of claims 37 to 41, wherein the central and peripheral nervous system associated disorder is treatable by a L-DOPA/AADC therapy.

### Claim 43 (depends on 37, 38, 39, 40, 41, 42)

Use according to any one of claims 37 to 42, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.

### Claim 44 (depends on 1)

Package comprising a pharmaceutical composition comprising a compound of formula I as defined in claim 1, or a pharmacologically acceptable salt or ester thereof, in combination with instructions to administer said composition with a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.

### Claim 45 (depends on 44)

Package according to claim 44, wherein the dosing regimen is once daily.

### Claim 46 (depends on 44)

Package according to claim 44, wherein the dosing regimen is once every other day.

### Claim 47 (depends on 44, 45, 46)

Package according to any one of claims 44 to 46, wherein the central and peripheral nervous system associated disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.

### Claim 48 (depends on 47)

Package as claimed in claim 47, wherein the movement disorder is restless leg syndrome, Parkinson's disease or a pathological state involving Parkinsonism.

### Claim 49 (depends on 44, 45, 46, 47, 48)

Package according to any one of claims 44 to 48, wherein the package further comprises a pharmaceutical composition comprising L-DOPA and/or an AADC.

### Claim 50 (depends on 44, 45, 46, 47, 48, 49)

Package according to any one of claims 44 to 49, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.
